Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

This results in the neuronal dysfunction and loss that ultimately leads to Parkinson’s disease. ... Currently, an estimated seven to ten million people are living with Parkinson’s across the globe, making it the second most common neurodegenerative

Latest news

  • Lilly buys biotech firm Disarm Therapeutics for $135m Lilly buys biotech firm Disarm Therapeutics for $135m

    Lilly has previously tried its hand in neurodegeneration therapy development, but took a serious hit earlier this year when its promising potential Alzheimer’s disease treatment failed in a phase 3 ... trial. The anti-amyloid candidate, solanezumab,

  • FDA sets November date for expert panel review of Biogen’s aducanumab FDA sets November date for expert panel review of Biogen’s aducanumab

    Advisory committee will review biologics license application for controversial therapy. The US Food and Drug Administration (FDA) panel is set to review Biogen’s controversial Alzheimer’s disease treatment aducanumab on ... The experimental

  • Stop that! Stop that!

    areas like Alzheimer’s disease. ... To be clear, this complex system’s view of their market was less comfortable than their reductionist view but it was a much more authentic one.

  • Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track Biogen’s highly-anticipated Alzheimers drug wins FDA fast-track

    Biogen has picked up a US Food and Drug Administration (FDA) fast-track review for its experimental Alzheimer’s disease treatment aducanumab. ... If approved, aducanumab will become the first treatment to reduce the clinical decline of Alzheimer’s

  • Biogen pays Denali $1bn upfront for Parkinson’s disease programme Biogen pays Denali $1bn upfront for Parkinson’s disease programme

    Mutations in the LRRK2 gene, a regulator of lysosomal function, can cause Parkinson’s disease and is thought to contribute to neurodegeneration. ... Biogen is currently awaiting a decision on its controversial Alzheimer’s disease therapy aducanumab

More from news
Approximately 69 fully matching, plus 327 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    reduction in tauopathy,” said Paul Aisen, director of the Alzheimer’s Therapeutic Research Institute, at the Clinical Trials on Alzheimer’s Disease meeting where Biogen presented its data. ... Canaccord Genuity analysts forecast peak sales of

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimers disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Now, interest is growing in a largely-untapped approach to targeting disease-associated proteins, particularly those that for many years have been considered ‘undruggable’. ... C4 also has a collaboration in place with Biogen focusing on neurological

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    The test works by identifying amyloid-beta (Abeta) proteins, which build up on the brains of those living with Alzheimer’s and which have a key link to the disease, although ... Alzheimer’s R&D has had to diversify as companies and researchers become

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimers disease

    Yet more than 100 years after the discovery of Alzheimer’s disease, we still do not have a cure. ... Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present.

More from intelligence
Approximately 5 fully matching, plus 29 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • July 2020: diversity and inclusion in clinical trials round-up July 2020: diversity and inclusion in clinical trials round-up

    Plus, research shows that the pathophysiology of Alzheimer’s disease varies between African American and white individuals. ... So surely it is not right, that the majority of patients in Alzheimer’s disease trials over the past few decades, have all

  • Outsourcing in Clinical Trials 2020 Virtual Conference Outsourcing in Clinical Trials 2020 Virtual Conference

    By 2040, over half of US people living with Alzheimer’s disease will be black or Hispanic. ... By 2050, Alzheimer’s disease cases in China will account for half of all global cases.

  • Digital therapeutics and their impact on society

    Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic? ... This is in part due to the explosive, bordering on unmanageable, increase in chronic

  • Are we ready for an Alzheimer's disease modifying treatment

    Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. ... However, Alzheimer’s disease-modifying treatments (DMTs) have not progressed as much in the last 15 years as we all hoped.

  • Diagnosing the lag in neuropsychiatric treatments

    Europe spends £690 billion a year on brain disorders, more than both cardiovascular disease and oncology combined. ... Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and

More from PMHub
Approximately 2 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...
Love in the Time of Coronavirus
Having gone through 4 stages of coping with covid-19: first disbelief, then humour, then creative ways to deal with isolation, and finally the tragic realisation that lives are being lost...
The other side of … multiple sclerosis
No good comes from excluding patients from having a say in their own care. In fact, improving activation (& outcomes) demands it....

Infographics